Skip to main content Accessibility help
×
Home

Schizophrenia, neuroleptic medication and mortality

  • Matti Joukamaa (a1), Markku Heliövaara (a2), Paul Knekt (a2), Arpo Aromaa (a2), Raimo Raitasalo (a3) and Ville Lehtinen (a4)...

Abstract

Background

There is an excess of death from natural causes among people with schizophrenia.

Aims

Schizophrenia and its treatment with neuroleptics were studied for their prediction of mortality in a representative population sample of 7217 Finns aged ⩾30 years.

Method

A comprehensive health examination was carried out at baseline. Schizophrenia was determined using the Present State Examination and previous medical records.

Results

During a 17-year follow-up, 39 of the 99 people with schizophrenia died. Adjusted for age and gender, the relative mortality risk between those with schizophrenia and others was 2.84 (95% CI 2.06–3.90), and was2.25 (95%CI1.61–3.15) after further adjusting for somatic diseases, blood pressure, cholesterol, body mass index, smoking, exercise, alcohol intake and education. The number of neuroleptics used at the time of the baseline survey showed a graded relation to mortality. Adjusted for age, gender, somatic diseases and other potential risk factors for premature death, the relative risk was 2.50 (95% CI1.46–4.30) per increment of one neuroleptic.

Conclusions

There is an urgent need to ascertain whether the high mortality in schizophrenia is attributable to the disorder itself or the antipsychotic medication.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Schizophrenia, neuroleptic medication and mortality
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Schizophrenia, neuroleptic medication and mortality
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Schizophrenia, neuroleptic medication and mortality
      Available formats
      ×

Copyright

Corresponding author

Dr Matti Joukamaa, Department of Social Psychiatry, Tampere School of Public Health, University of Tampere, FIN-33014, Finland. E-mail: matti.joukamaa@uta.fi

Footnotes

Hide All

See invited commentary, p. 128, this issue.

Declaration of Interest

None.

Footnotes

References

Hide All
Aromaa, A., Heliovaara, M., Impivaara, O., et al (1989) Aims, methods and study population. Part I. In The Execution of the Mini-Finland Health Survey (eds Aromaa, A., Heliovaara, M., Impivaara, O., et al). Publication no. ML: 88. He sinki: Socia Insurance Institution.
Bralet, M. C., Yon, V., Loas, G., et al (2000) Causes de la mortalité chez les schizophrènes: étude prospective sur 8 ans d'une cohorte de 150 schizophrenes chroniques. Encéphale, 26, 3241.
Brown, S. (1997) Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry, 171, 502508.
Brown, S., Inskip, H. & Barraclough, B. (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212217.
Cox, D. R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society B, 34, 187220.
Goldberg, D. P. (1972) The Detection of Psychiatric Illness by Questionnaire. Maudsley Monograph 21. London: Oxford University Press.
Harris, E. C. & Barraclough, B. (1998) Excess mortality of mental disorder. British Journal of Psychiatry, 173, 1153.
Heilä, H. & Lonnqvist, J. (2003) The clinical epidemiology of suicide in schizophrenia. In The Epidemiology of Schizophrenia (eds Murray, R., Jones, P., Susser, E., et al), pp. 288316. Cambridge: Cambridge University Press.
Joseph, K. S., Blais, L., Ernst, P., et al (1996) Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers. BMJ, 31, 7982.
Joukamaa, M., Heliovaara, M., Knekt, P., et al (2001) Mental disorders and cause-specific mortality. British Journal of Psychiatry, 179, 498502.
Lehtinen, V., Joukamaa, M., Jyrkinen, E., et al (1990a) Prevalence of mental disorders among adults in Finland. Basic results from the Mini-Finland Health Survey. Acta Psychiatrica Scandinavica, 81, 418425.
Lehtinen, V., Joukamaa, M., Jyrkinen, E., et al (1990b) Need for mental health services of the adult population in Finland: results from the Mini-Finland Health Survey. Acta Psychiatrica Scandinavica, 81, 426431.
Mäkelä, M., Heliövaara, M., Sievers, K., et al (1993) Musculoskeletal disorders as determinants of disability in Finns aged 30 years or more. Journal of Clinical Epidemiology, 46, 549559.
Montout, C., Casadebaig, F., Lagnaoui, R., et al (2002) Neuroleptics and mortalityin schizophrenia: prospective analysis of deathsin a French cohort of schizophrenic patients. Schizophrenia Research, 57, 147156.
Mortensen, P. B. (2003) Mortalityand physical illnessin schizophrenia. In The Epidemiology of Schizophrenia (eds Murray, R., Jones, P., Susser, E., et al), pp. 275287. Cambridge: Cambridge University Press.
Osby, U., Correia, N., Brandt, L., et al (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research, 45, 2128.
Ray, W. A. & Meador, K. G. (2002) Antipsychotics and sudden death: is thioridazine the only bad actor? British Journal of Psychiatry, 180, 483484.
Ray, W. A., Meredith, S., Thapa, P. B., et al (2001) Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58, 11611167.
SAS Institute (1997) SAS/STAT Software: Changes and Enhancements through Release 612. Cary, NC: SAS Institute.
Thomassen, R., Vandenbroucke, J. P. & Rosendaal, F. R. (2001) Antipsychotic medication and venous thrombosis. British Journal of Psychiatry, 179, 6366.
Vaisanen, E. (1975) Psychiatric disorders in Finland. Acta Psychiatrica Scandinavica Supplementum, 263, 2233.
Waddington, J. L., Youssef, H. A. & Kinsella, A. (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325329.
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974) The Measurement and Classification of Psychiatric Symptoms. London: Cambridge University Press.
Wing, J. K., Mann, S. A., Leff, J. P., et al (1978) The concept of a case in psychiatric population surveys. Psychological Medicine, 8, 203217.
Wirshing, D. A., Pierre, J. M., Erhart, S. M., et al (2003) Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatric Clinics of North America, 26, 165190.
Witchel, H. J., Hancox, J. C. & Nutt, D. J. (2003) Psychotropic drugs, cardiac arrhythmia, and sudden death. Journal of Clinical Psychopharmacology, 23, 5877.
World Health Organization (1974) Eighth Revision of the International Classification of Diseases and Related Health Problems (ICD-8). Geneva: WHO.

Schizophrenia, neuroleptic medication and mortality

  • Matti Joukamaa (a1), Markku Heliövaara (a2), Paul Knekt (a2), Arpo Aromaa (a2), Raimo Raitasalo (a3) and Ville Lehtinen (a4)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Schizophrenia, neuroleptic medication and mortality

  • Matti Joukamaa (a1), Markku Heliövaara (a2), Paul Knekt (a2), Arpo Aromaa (a2), Raimo Raitasalo (a3) and Ville Lehtinen (a4)...
Submit a response

eLetters

We encountered an error trying to retrieve eLetters for this article. Please try again or contact Customer Services

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *